专题：Chemotherapy-induced cardiotoxicity and mitigation

This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.
最新文献
Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study

article Full Text OpenAlex

Age‐ and sex‐specific modulation of human cardiac electrophysiology by doxorubicin

article Full Text OpenAlex

Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South Korea

article Full Text OpenAlex

Polygenic Risk for Cardiometabolic and Cardiovascular Disease in a Multiethnic Cohort of Breast Cancer Survivors

article Full Text OpenAlex

Life-Threatening Cardiogenic Shock During Chemotherapy

article Full Text OpenAlex

Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients

article Full Text OpenAlex

A MOF-based nanoplatform integrating cardioprotection with chemo-photothermal therapy for safer cancer treatment

article Full Text OpenAlex

Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association

article Full Text OpenAlex

Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-caspase-3/GSDME axis and M1 polarization of macrophages

article Full Text OpenAlex

A toxicological report on drug-induced toxicity evaluation: integrated preclinical findings from in vitro and in vivo studies to human risk prediction and lethal outcomes, including teratogenic effects and mortality

article Full Text OpenAlex

近5年高被引文献
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

article Full Text OpenAlex 2488 FWCI378.2284

Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

review Full Text OpenAlex 645 FWCI150.6758

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

article Full Text OpenAlex 464 FWCI73.3887

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

review Full Text OpenAlex 381 FWCI84.9338

Cardiovascular Disease Risk Among Cancer Survivors

article Full Text OpenAlex 271 FWCI39.8935

Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming

review Full Text OpenAlex 244 FWCI54.3933

Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches

review Full Text OpenAlex 234 FWCI35.9556

Management of common clinical problems experienced by survivors of cancer

article Full Text OpenAlex 225 FWCI22.608

Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity

review Full Text OpenAlex 219 FWCI31.8546

Cardiovascular disease and cancer: shared risk factors and mechanisms

review Full Text OpenAlex 215 FWCI51.8295